Contents
Antibiotics during Premature Labor may Increase Risk of Infant’s Cerebral Palsy.
Just found this article that discusses a scientific study conducted by researchers from Oxford University that shows how infant’s risk of developing cerebral palsy actually increases with the use of antibiotics
Bioabsorable Stents by Abbot Inc.
These post discuses the video titled “Abbott Inc.’s Bioabsorbable Stent: Opportunities for Market Dominance“. This post provides articles and videos for different sorts of treatment for cardiovascular diseases. These treatments include the following: 1) LifeStyle Changes, 2) Medications, 3) Angioplasty (PCI: Percutaneous Coronary Intervention) and 4) Surgery (CABG: Cardiovascular Artery Bypass Graft)
Research And Markets
This post provides a link to “Research And Markets” website. This organization is the leading source for international market research and market data related to Pharmaceuticals and HealthCare.
Staying in Touch/Reconnecting via LinkedIn
This post discusses how professionals should stay in touch or reconnect after coming in contact via LinkedIn.
This post provides information on the AstraZeneca Seminars that are held at UTM, in collaboration with the MBiotech program of UTM.
Panel Suggests Using Inmates in Drug Trials
This post discusses the article “Panel Suggests Using Inmates in Drug Trials”. In August 2006, Institute of Medicine of the National Academy of Sciences recommended that the regulations regarding conducting experiments in inmates be loosened. The post also highlights an article by Vera Hassner Sharav posted at the ‘The Alliance for Human Research Protection” (AHRP). This article discusses the ethical implications of loosening the regulations surrounding clinical trials on inmates.
Massive Brainstorms Expected: Inc. Research, Academia, Government, Scientists and Investors
This post provides information on a Biotech/Life Sciences Brainstorming Seminar that was held at Metro Toronto Convention on May-11 & 12, 2009.
Alba Bioscience receives funding to secure 16 R&D jobs
This post provides an excerpt from an article that talks about how Alba Biosciences received funding to secure 16 R&D jobs during recession.
Merger of PRA International and CroMedica
This particular article discusses some benefits and potential challenges of the Merger of PRA International and CroMedica .
This post reviews an article titled “Racism and Health: Antiracism is an Important Health Issue”. It discusses the evil of racism and the need to eliminate it on a societal level. It also provides links to two scientific studies where scientists studied the effects of racism on varying populations.
This article discusses how AIDS have been cured by Dr. Gero Huetter, a hematologist who cured a 42 year old leukemia patient with a bone marrow transplant constituting of a unique genetic mutations, Delta 32, in its recessive form, has managed to cure AIDS.
This article provides an excerpt and link to an article titled “Australian scientists develop potential “blockbuster” diabetes drug”.
The Effects of the Milken Institute’s 2004 Biotech Index on US Biotech Centres
This article summarizes the effects of Milken’s Biotech Index (product of untiring research by Milken Institute and Deloitte) on the global economy. The index is a measurement of “economic outcomes” and “efficiency in functions” of 21st century biotechnology clusters within U.S. and the world. This post is a summary of information contained in two articles that are mentioned in the Reference section.
The Challenge of Managing R&D Bottlenecks
This article reviews an article titled “Improving Efficiency: To elminate R&D bottlenecks, drug companies are evaluating all phases of discovery and development and are using novel approaches to speed them up.” In this article, the author Stu Borman discusses advances that have been made in the pharmaceutical industry to ensure efficient Research and Development procedures. The article proved really informative since it walks the reader through all steps of the development of a medicinal compound, while pointing out different crucial procedures that have been developed to ensure efficient and accurate discovery of the drugs. In the end of this post, I have added my commentary with regards to specific scientific areas such as Proteomics, Chemogenomics as well as Radiolabelling.
Impacts of Proteomics in the Pharma Market
This post reviews an article titled “The Proteomics Toolbox – A Review of the Newest Drug Discovery Methods” by Dr. Andrea Kopke. At the end of this review, I have provided three reasons why I personally believe that the pharmaceutical companies should switch to Proteomics based tools if they wish to develop successful and less expensive medications.
Outsource Almost Everything
This article reviews an article by John Simons titled “The Pharma of Tommorrow”. In this article, I discuss how William Haseltine, founder and ex-CEO of Human Genome Sciences believes that the future success of the pharmaceutical industry depends on outsourcing almost anything. I have reviewed this article and presented three key issues that should be kept in viewpoint while implementing Haseltine’s idea.
Efficacy Requirements of the FDCA- a safeguard or a headache?
This post reviews the article titled “The Price We Pay: The Efficacy Requirement for New Drugs Under the Food, Drug and Cosmetic Act”. Author, Corey B. Rubenstein provides three reasons why he/she thinks that the efficacy requirement for the NDA must be waived. In this article, I have reviewed Corey’s opinion as well as that of his critics and then provided my humble opinion at the very end.
Managing High Cost of Drugs
In this post, I have reviewed an article titled “Back-Breaking Drug Costs-Rising Prices of Prescriptions force Older Patients to Make Trade-offs”. In this article, author Cathryn Domrose points out the battle between the pharmaceutical industry and the public with regards to the cost of the pharmaceutical products. I have reviewed this article in detail as well as provided my opinion at the very end.
Would the BlockBuster Model Really Work?
In this post, I have reviewed an article titled “Blockbusters to the Rescue! Can anything go right for Big Pharma? With a crop of mega-selling meds set to roll out, the industry may be on the mend.” In this article, author John Simons, argues that blockbuster drug model is going to save the future of the pharmaceuticals. However, I tend to disagree since readings have shown me that blockbuster drugs have actually placed too much pressure on the manufacturers. I have further commented how in my opinion, the pharmaceutical companies may make ample profit from its blockbuster drugs.
How to Avoid Allowing these Cheap, Effective Drugs go Unused?
This post discusses an article by Matthew Herper, titled “Why Cheap Effective Drugs Go Unused?” After reading this article, I brainstormed three ways corporate companies may be able to utilize that big pool of cheap, effective, old drugs that usually go unused because these big companies don’t see any profit in investing in them.
This article discusses how William Haseltine, founder and ex-CEO of Human Genome Sciences, believes that in order to relieve the pharma industry of stress and to increase innovation, the big giants must give way to small mutually collaborating corporations
careerxpert001
